Is elimination of HCV in 2030 realistic in Central Europe

According to the recent data presented by Central‐European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one p...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2021-06, Vol.41 (S1), p.56-60
Main Authors: Flisiak, Robert, Zarębska‐Michaluk, Dorota, Frankova, Sona, Grgurevic, Ivica, Hunyady, Bela, Jarcuska, Peter, Kupčinskas, Limas, Makara, Michael, Simonova, Marieta, Sperl, Jan, Tolmane, Ieva, Vince, Adriana, Valenti, Luca
Format: Article
Language:English
Subjects:
COVID-19
epidemiology
hepatitis C virus
liver
Patients
therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to the recent data presented by Central‐European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid‐19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14834